Atle Fund Management AB Purchases 8,299 Shares of Edwards Lifesciences Corporation $EW

Atle Fund Management AB increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 14.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 65,659 shares of the medical research company’s stock after buying an additional 8,299 shares during the quarter. Edwards Lifesciences accounts for about 2.0% of Atle Fund Management AB’s portfolio, making the stock its 19th biggest holding. Atle Fund Management AB’s holdings in Edwards Lifesciences were worth $5,106,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of EW. Rosenberg Matthew Hamilton bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $28,000. True Wealth Design LLC lifted its position in shares of Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after purchasing an additional 259 shares in the last quarter. NewSquare Capital LLC boosted its holdings in Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after purchasing an additional 134 shares during the last quarter. Rakuten Securities Inc. grew its position in Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares in the last quarter. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at $30,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE:EW opened at $81.28 on Friday. The company has a market cap of $47.17 billion, a P/E ratio of 35.04, a P/E/G ratio of 3.14 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The firm’s fifty day moving average price is $84.76 and its two-hundred day moving average price is $80.99. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business’s revenue was up 14.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.67 earnings per share. Equities analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the sale, the vice president owned 22,002 shares of the company’s stock, valued at $1,885,571.40. This represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the firm’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total value of $971,384.40. Following the transaction, the vice president owned 31,870 shares in the company, valued at approximately $2,729,984.20. This trade represents a 26.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 57,824 shares of company stock valued at $4,863,323 in the last quarter. Company insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the subject of several analyst reports. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a report on Monday, November 3rd. Barclays reissued an “overweight” rating and set a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. Piper Sandler reaffirmed an “overweight” rating and set a $98.00 price target (up previously from $95.00) on shares of Edwards Lifesciences in a research report on Tuesday, January 20th. TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Finally, Truist Financial set a $92.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, December 5th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average price target of $96.82.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.